Vireo Growth (VREOF) EPS (Diluted) Growth (3y) (2023 - 2026)
Vireo Growth (VREOF) EPS (Diluted) Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EPS (Diluted) Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 43.94 Bn | 42.97 Bn | - | - |
| 2 | Teva Pharmaceutical Industries | 43.00 Bn | 39.35 Bn | 2.15 Bn | 15.17% |
| 3 | Zoetis | 31.60 Bn | 29.93 Bn | 1.05 Bn | 3.25% |
| 4 | Takeda Pharmaceutical | 28.61 Bn | 22.81 Bn | 5.10 Bn | 2.66% |
| 5 | United Therapeutics | 22.12 Bn | 19.46 Bn | 683.80 Mn | 11.56% |
| 6 | Viatris | 18.75 Bn | 17.86 Bn | 1.46 Bn | -35.09% |
| 7 | Neurocrine Biosciences | 15.57 Bn | 15.18 Bn | 935.80 Mn | 13.29% |
| 8 | Elanco Animal Health | 11.74 Bn | 11.21 Bn | 798.00 Mn | 36.48% |
| 9 | Dr Reddys Laboratories | 10.12 Bn | 9.95 Bn | - | - |
| 10 | Vireo Growth | 491.44 Mn | 349.14 Mn | 95.30 Mn | -30.66% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 31.96% |
| Dec 31, 2025 | 14.09% |
| Sep 30, 2025 | 26.80% |
| Jun 30, 2025 | 28.82% |
| Mar 31, 2025 | 27.98% |
| Dec 31, 2024 | 30.16% |
| Sep 30, 2024 | 33.95% |
| Jun 30, 2024 | 35.86% |
| Mar 31, 2024 | 34.29% |
| Dec 31, 2023 | 41.34% |
| Sep 30, 2023 | -42.14% |
| Jun 30, 2023 | 29.24% |